Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer

NCT06493240 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Rectal Cancer

Interventions

RADIATION: radiation
DRUG: PD-1 Monoclonal Antibody
PROCEDURE: TME surgery

Sponsor

Peking University People's Hospital